Overindulging in rich foods while taking a drug like Wegovy or Zepbound can raise the risk of side effects like nausea and ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

Shares of Novo Nordisk A/S took a dive in early Monday trading after the drugmaker said oral semaglutide, which is the key ingredient in the company's Ozempic and Wegovy diabetes and weight-loss drugs ...

A new once-daily weight loss pill developed by Novo Nordisk has shown strong results in helping people with obesity lose ...